Research programme: CCNA2 gene therapy - VentriNova

Drug Profile

Research programme: CCNA2 gene therapy - VentriNova

Alternative Names: Cyclin A2 gene therapy - VentriNova; VN-100; VN-200

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VentriNova
  • Class Gene therapies
  • Mechanism of Action Cyclin-dependent kinase modulators; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Myocardial infarction

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Myocardial-infarction in USA
  • 25 Feb 2014 VentriNova is open to partnering opportunities for development of this research programme.
  • 19 Feb 2014 Preclinical trials in Myocardial infarction in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top